GSK Seeks Approval Of Advanced Breast Cancer Drug For First-Line Treatment

News — By on April 6, 2009 at 3:00 am

GlaxoSmithKline on Wednesday applied for approval to market its breast cancer drug Tykerb in U.S. and Europe as a first-line treatment for women with advanced, hormone-sensitive breast cancer, the AP/Google.com reports. Tykerb, known as Tyverb in Europe, was approved two years ago in the U.S.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback